NCT07516314

ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant Patients

ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant (HCT) Patients (ACTivate)

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 476 (estimated)
• Sponsor: Anthony Sung, MD · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This study is a phase 2, multicenter, randomized controlled trial to test the application of Acceptance and Commitment Therapy (ACT) in HCT patients. ACT is an evidence-based cognitive behavioral therapy intervention that emphasizes psychological flexibility and behaviors, helping transplant patients focus on actions that may help maintain adequate physical activity despite physical and emotional discomfort.

Conditions

• Stem Cell Transplant Patients

Interventions

Type	Name	Description
BEHAVIORAL	ACTivate sessions	ACTivate sessions are based on ACT and train psychological flexibility skills to help patients and caregivers adhere to recommendations for physical activity and nutrition in the face of an uncertain and difficult treatment course, side effects and complications. Sessions will be conducted conjointly (include both the patient and caregiver). . Interventionists will be master's level psychology professionals. All sessions will be conducted remotely and audiotaped.

Timeline

• Start date: 2026-05-01
• Primary completion: 2030-01-01
• Completion: 2031-04-01
• First posted: 2026-04-07
• Last updated: 2026-04-07

Locations

2 sites across 1 country: United States